Dec 06, 2022 / 10:00AM GMT
Kevin M. Herde - Maravai LifeSciences Holdings, Inc. - Executive VP & CFO
All right. Good morning, everybody. My name is Kevin Herde. I'm the Executive Vice President and CFO of Maravai LifeSciences. I'm going to go through a few overview slides for you all here this morning, and then I'm going to sit down with Matthew and go through a little bit of Q&A. So hopefully, we get a lot covered here in the next 27 minutes roughly.
Just -- obviously, we might talk about some forward-looking statements here and just our normal disclosures with regards to some of these non-GAAP measures. We talk a lot about adjusted EBITDA as one of our non-GAAP measures of the company.
So who is Maravai? So we are a life science tools, products and services provider and we operate in a couple of distinct segments, one which is supporting our customers in providing highly modified complex nucleic acids. We call that segment Nucleic Acid Production. And certainly, one of the largest products we have within that segment is supporting messenger -- mRNA predominantly through both our mRNA services offering as
Maravai LifeSciences Holdings Inc at Nasdaq Investor Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers